

## Medroxyprogesterone Tablets

August 10, 2011

All medroxyprogesterone (MPA) tablets are currently shorted.

### Products listed on formulary:

Strength	Name	DIN
2.5 mg	Novo-Medrone	02221284
	Apo-Medroxy	02244726
	Nu-Medroxy	02252740
	Provera	00708917
5 mg	Novo-Medrone	02221292
	Apo-Medroxy	02244727
	Nu-Medroxy	02252759
	Provera	00030937
10 mg	Novo-Medrone	02221306
	Apo-Medroxy	02277298
	Provera	00729973

### Products not on formulary listed on DPD

Strength	Name	DIN
100 mg	Apo-Medroxy	02267640

- Bulk MPA is available for compounding from Medisca.

Alternatively, use different progestins:

Indications and Doses of Different Progestins		
Indication	Progestin	Usual Dose
Hormone Therapy	MPA	2.5 mg* daily continuously 5-10 mg for 12-14 days
	Micronized Progesterone (Prometrium)	100*-200*mg HS continuously 200-300*mg for last 12-14 days of cycle
	Norethindrone acetate* (Micronor, Norlutate)	0.35-0.7 mg daily continuously
Secondary Amenorrhea	MPA	5 – 10 mg daily for 12-14 days every month

Saskatchewan Drug Information Service  
Telephone: 1-800-667-3425 (SK); 966-6340 (Saskatoon)  
Fax: (306) 966-2286  
[www.druginfo.usask.ca](http://www.druginfo.usask.ca)

	Micronized Progesterone*	200 mg daily for 10-14 days every month
	Norethindrone acetate	2.5 to 10 mg starting with the fifth day of the menstrual cycle and ending on the 25 <sup>th</sup> day.
<b>Dysfunctional Uterine Bleeding</b>	MPA	5-10 mg for 10-14 days
	Norethindrone acetate	2.5 to 10 mg starting with the fifth day of the menstrual cycle and ending on the 25 <sup>th</sup> day.
<b>Metastatic Endometrial Carcinoma</b>	MPA	200-400 mg/day is the usual dose. See CPS for more information
	Megestrol acetate (Megace OS)*	160-320 mg daily
<b>Metastatic Breast Cancer</b>	MPA	400 mg daily, given in divided doses. See CPS for more information
	Megestrol acetate*	40 mg QID

\*Not a labeled indication or dose

**\*\*Note: Prometrium® is usually EDS on the Saskatchewan Drug Plan. However, it is full formulary for two months during the manufacturer shortage of MPA tablets.**

**Alternatively, consider other combination products (usual doses):**

- Oral:
  - Activelle one tablet daily
  - Angeliq one tablet daily
  
- Transdermal:
  - Climara Pro 45 mcg weekly
  - Estalis 50 mcg twice weekly

## References:

1. Saskatchewan Formulary, Drug Plan and Extended Benefits Branch [homepage on the Internet]. Government of Saskatchewan; [updated 2011 Jul 28; cited 2011 Aug 10]. Available from: <http://formulary.drugplan.health.gov.sk.ca/>
2. Health Canada. Drug Product Database Online Query. Ottawa, ON: Health Canada; [updated 2011 Aug 9; cited 2011 Aug 10]. Available from: <http://webprod.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng>
3. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2011 [updated 2011 Aug 10; cited 2011 Aug 10]. Provera® [product monograph]. Available from: <http://www.e-cps.ca> . Also available in paper copy from the publisher.
4. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2011 [updated 2011 Aug 10; cited 2011 Aug 10]. Prometrium® [product monograph]. Available from: <http://www.e-cps.ca> . Also available in paper copy from the publisher.
5. Erfa Canada Inc. Norlutate® [monograph]. Montreal, QC. 2010 Nov 29.
6. Regier L. Postmenopausal Pharmacotherapy: Comparison Chart. RxFiles drug comparison charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010-11. p. 90. Available from: [www.RxFiles.ca](http://www.RxFiles.ca). Accessed 2011 Aug 10.
7. ACP PIER®: The Physicians' Information and Education Resource BOOK ONLINE. Jackson, WY, Teton Data Systems, 2011: Based on: ACP PIER and AHFS DI® Essentials. Philadelphia, PA: American College of Physicians; 2011. STAT!Ref Medical Reference Library. Available from <http://online.statref.com/document.aspx?fxid=92&docid=2> Accessed 2011 Aug 10
8. Cullimore AJ. Menopause. In: Gray Jean, editor. e-Therapeutics+ [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2011 [updated May 2011; cited 2011 Aug 10]. Available from: <http://www.e-therapeutics.ca>. Also available in paper copy from the publisher.
9. Ellis M, Hayes DF, Naughton MJ, et al. Systemic treatment for metastatic breast cancer: Endocrine therapy. Last updated 2011 Feb 17. Last literature review 2011 May; cited 2011 Aug 10. Available from [www.uptodate.com](http://www.uptodate.com). Subscription and login required.
10. Plaxe SC, Mundt AJ. Treatment of advanced or recurrent endometrial cancer. Last updated 2011 Feb 18. Last literature review 2011 May; cited 2011 Aug 10. Available from [www.uptodate.com](http://www.uptodate.com). Subscription and login required.
11. Phone communication with Vanessa, Medisca Inc. Saskatchewan representative, 1-800-665-6334. 2011 Aug 11.
12. Phone communication with Evelyn, Saskatchewan Prescription Drug Plan, 1-306-787-8744. 2011 Aug 11.